NDAINJECTIONINJECTABLE1 Generic Approved
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDENE (nicardipine hydrochloride) is an injectable calcium channel blocker approved in 1992 for acute hypertension management. It is administered intravenously to rapidly lower blood pressure in hospitalized patients experiencing hypertensive emergencies or perioperative hypertension. The drug works by blocking calcium influx into vascular smooth muscle cells, causing vasodilation and reduced peripheral vascular resistance.
LOE Approaching1.3 years to LOE
With LOE approaching in 1.3 years and moderate competitive pressure (30), commercial teams should expect resource consolidation and focus shift toward generic transition planning and market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on CARDENE at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.